Consolidated Statements of Operations (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Revenue
Operating expenses:
General and administrative	302,877	320,228
Depreciation	207	347
Research and development	90,988	123,325
Total operating expenses	394,072	443,900
Loss from operations	(394,072)	(443,900)
Other expense:
Interest expense, net	104,340	117,602
Total other expense	104,340	117,602
Net loss	(498,412)	(561,502)
Net loss attributable to the noncontrolling interest	515	505
Net loss applicable to Bion's common stockholders	$ (497,897)	$ (560,997)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.02)	$ (0.02)
Weighted-average number of common shares outstanding: Basic and diluted (in shares)	30,793,634	27,466,812